- Conditions
- Aneurysm, Brain
- Interventions
- WAVE, as part of the SMART COIL System
- Device
- Lead sponsor
- Penumbra Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 572 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 34
- States / cities
- Dothan, Alabama • Tucson, Arizona • La Mesa, California + 29 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 1,348
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Respiratory Depression
- Interventions
- Expiron respirator
- Device
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Healthy
- Interventions
- Within-Subject Active vs. Placebo Topical Applications
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Gastrointestinal Cancer
- Interventions
- Raludotatug Deruxtecan (R-DXd)
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 8
- States / cities
- New Haven, Connecticut • Washington D.C., District of Columbia • Miami Beach, Florida + 5 more
- Conditions
- Anal Canal Squamous Cell Carcinoma, Metastatic Anal Canal Carcinoma, Stage IV Anal Cancer AJCC v8
- Interventions
- Biospecimen Collection, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab
- Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 55
- States / cities
- Los Angeles, California • Sacramento, California • Aurora, Colorado + 43 more
- Conditions
- Endometrial Cancer
- Interventions
- Carboplatin/Paclitaxel, Trastuzumab
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- Female only
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2022
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Concord, California + 16 more
- Conditions
- Migraine
- Interventions
- Galcanezumab, Erenumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Newport Beach, California • Waterbury, Connecticut
- Conditions
- Aortic Aneurysm
- Interventions
- Endovascular Repair, Standard Open Repair
- Procedure
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 50 Years and older
- Enrollment
- 881 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2012
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Tucson, Arizona • No. Little Rock, Arkansas + 39 more
- Conditions
- Disability Diagnosis
- Interventions
- RDDT
- Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 635 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut
- Conditions
- NYHA Class III Heart Failure, NYHA Class IV Heart Failure
- Interventions
- Optimizer System, No intervention: Optimal medical therapy
- Device · Other
- Lead sponsor
- Impulse Dynamics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 32
- States / cities
- Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 26 more
- Conditions
- HIV Infections
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 3,669 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2006
- U.S. locations
- 91
- States / cities
- Mill Valley, California • Oakland, California • San Francisco, California + 31 more
- Conditions
- Diabetes, Stroke, Obesity
- Interventions
- Not listed
- Lead sponsor
- Children's & Women's Health Centre of British Columbia
- Other
- Eligibility
- Not listed
- Enrollment
- 626 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 4
- States / cities
- New Haven, Connecticut • Louisville, Kentucky • Camden, New Jersey + 1 more
- Conditions
- Aortic Aneurysm, Abdominal
- Interventions
- Endurant Stent Graft System
- Device
- Lead sponsor
- Medtronic Cardiovascular
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 24
- States / cities
- Los Angeles, California • Stanford, California • New Haven, Connecticut + 20 more
- Conditions
- Head and Neck Carcinoma of Unknown Primary, Head and Neck Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Sinonasal Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Sinonasal Squamous Cell Carcinoma AJCC v7
- Interventions
- Berzosertib, Cisplatin, Computed Tomography, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Positron Emission Tomography, Radiation Therapy
- Drug · Procedure · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 19
- States / cities
- Duarte, California • Sacramento, California • New Haven, Connecticut + 13 more
- Conditions
- COVID-19 Pneumonia
- Interventions
- Tofacitinib 10 mg, Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Myasthenia Gravis
- Interventions
- Nipocalimab, Placebo, Nipocalimab SC-LIV
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 24
- States / cities
- Paradise Valley, Arizona • Scottsdale, Arizona • Los Angeles, California + 21 more
- Conditions
- Carcinoma, Squamous Cell
- Interventions
- Pembrolizumab, Placebo
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 30
- States / cities
- Mobile, Alabama • Duarte, California • La Jolla, California + 26 more
- Conditions
- Colorectal Cancer
- Interventions
- Colonoscopy, Fecal immunochemical test (FIT)
- Procedure
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 50,126 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2028
- U.S. locations
- 45
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Fresno, California + 42 more
- Conditions
- Polycystic Ovarian Syndrome, Vitamin D Deficiency
- Interventions
- Vitamin D2 (Ergocalciferol), Medroxyprogesterone (Provera), Vitamin D3 (Cholecalciferol), Elemental Calcium
- Dietary Supplement · Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Heart Failure
- Interventions
- Torsemide, Furosemide
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,973 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 60
- States / cities
- Alexander City, Alabama • Huntsville, Alabama • Tucson, Arizona + 51 more
- Conditions
- Alzheimer's Disease
- Interventions
- PF-05212377 (SAM-760), Placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 40
- States / cities
- Costa Mesa, California • Imperial, California • Rancho Mirage, California + 29 more
- Conditions
- Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7
- Interventions
- Docetaxel, Durvalumab, Erlotinib Hydrochloride, FGFR Inhibitor AZD4547, Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Palbociclib, Pharmacological Study, Rilotumumab, Talazoparib, Taselisib, Tremelimumab
- Drug · Biological · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 1,864 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 998
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 639 more
- Conditions
- Small Cell Lung Carcinoma
- Interventions
- Tarlatamab, Pembrolizumab, CRS Mitigation Strategies
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 269 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 15
- States / cities
- Duarte, California • New Haven, Connecticut • Tampa, Florida + 12 more
- Conditions
- Atrial Fibrillation
- Interventions
- Weekly patient self-testing of prothrombin time, High quality anticoagulation management (HQACM) with conventional monthly testing
- Procedure · Other
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 2,922 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Fresno, California • Loma Linda, California + 25 more